1 Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516-527, doi:10.1038/s41586-020-2798-3 (2020).
2 Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
3 Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384, 403-416, doi:10.1056/NEJMoa2035389 (2021).
4 Falsey, A. R. et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med, doi:10.1056/NEJMoa2105290 (2021).
5 Sadoff, J. et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 384, 2187-2201, doi:10.1056/NEJMoa2101544 (2021).
6 Keech, C. et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med 383, 2320-2332, doi:10.1056/NEJMoa2026920 (2020).
7 Heath, P. T. et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med 385, 1172-1183, doi:10.1056/NEJMoa2107659 (2021).
8 Novavax Inc. Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia. last accessed: 12-JAN-2022, <https://ir.novavax.com/2021-11-01-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-Indonesia> (2021).
9 Novavax Inc. Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines. last accessed: 12-JAN-2022, <https://ir.novavax.com/2021-11-17-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-the-Philippines> (2021).
10 European Medicines Agency. EMA recommends Nuvaxovid for authorisation in the EU. <https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu> last accessed: 12-JAN-2022. (2021).
11 Krammer, F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med 27, 1147-1148, doi:10.1038/s41591-021-01432-4 (2021).
12 Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27, 1205-1211, doi:10.1038/s41591-021-01377-8 (2021).
13 Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423-4428, doi:10.1016/j.vaccine.2021.05.063 (2021).
14 Kristiansen, P. A. et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet 397, 1347-1348, doi:10.1016/s0140-6736(21)00527-4 (2021).
15 Goldblatt, D. et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine 40, 306-315, doi:10.1016/j.vaccine.2021.12.006 (2021).
16 Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43-50, doi:10.1126/science.abm3425 (2022).
17 Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 27, 2032-2040, doi:10.1038/s41591-021-01540-1 (2021).
18 Farcet, M. R., Karbiener, M., Schwaiger, J., Ilk, R. & Kreil, T. R. Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic. J Infect Dis, doi:10.1093/infdis/jiab142 (2021).
19 Schwaiger, J., Karbiener, M., Aberham, C., Farcet, M. R. & Kreil, T. R. No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic. J Infect Dis 222, 1960-1964, doi:10.1093/infdis/jiaa593 (2020).
20 Zollner, A. et al. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. EBioMedicine 70, 103539, doi:10.1016/j.ebiom.2021.103539 (2021).